<DOC>
	<DOCNO>NCT00411125</DOCNO>
	<brief_summary>This phase I study analyze bioavailability pharmacodynamic two different variant oral salmon calcitonin ( SMC021 ) postmenopausal woman</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Study Oral Salmon Calcitonin Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Healthy postmenopausal woman Previous treatment osteoporosis medication Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>Pharmacokinetics/dynamics</keyword>
	<keyword>Calcitonin</keyword>
</DOC>